PEPFAR's annual planning process is done either at the country (COP) or regional level (ROP).
PEPFAR's programs are implemented through implementing partners who apply for funding based on PEPFAR's published Requests for Applications.
Since 2010, PEPFAR COPs have grouped implementing partners according to an organizational type. We have retroactively applied these classifications to earlier years in the database as well.
Also called "Strategic Areas", these are general areas of HIV programming. Each program area has several corresponding budget codes.
Specific areas of HIV programming. Budget Codes are the lowest level of spending data available.
Expenditure Program Areas track general areas of PEPFAR expenditure.
Expenditure Sub-Program Areas track more specific PEPFAR expenditures.
Object classes provide highly specific ways that implementing partners are spending PEPFAR funds on programming.
Cross-cutting attributions are areas of PEPFAR programming that contribute across several program areas. They contain limited indicative information related to aspects such as human resources, health infrastructure, or key populations programming. However, they represent only a small proportion of the total funds that PEPFAR allocates through the COP process. Additionally, they have changed significantly over the years. As such, analysis and interpretation of these data should be approached carefully. Learn more
Beneficiary Expenditure data identify how PEPFAR programming is targeted at reaching different populations.
Sub-Beneficiary Expenditure data highlight more specific populations targeted for HIV prevention and treatment interventions.
PEPFAR sets targets using the Monitoring, Evaluation, and Reporting (MER) System - documentation for which can be found on PEPFAR's website at https://www.pepfar.gov/reports/guidance/. As with most data on this website, the targets here have been extracted from the COP documents. Targets are for the fiscal year following each COP year, such that selecting 2016 will access targets for FY2017. This feature is currently experimental and should be used for exploratory purposes only at present.
Under the World Health Organization (WHO) Umbrella Grant, during FY 2009 WHO received funding to provide targeted technical assistance to support HIV/AIDS programming in medication assisted treatment (MAT). WHO will conduct this technical assistance in FY 2010 and receive additional funding for continued technical assistance. WHO strategic technical support will provide critical direction to Ukraine's MAT programming. It is expected that WHO will achieve the following outcomes by the end of its second year of assistance:
A review of the cost effectiveness of existing MAT models
A quality assurance assessment of the delivery of integrated MAT packages
WHO's technical assistance directly contributes the achievement of two of Ukraine's forthcoming Partnership Framework goals and benchmarks. These are: the reduction of HIV transmission among most-at-risk populations (MARPs); and improved quality and cost effectiveness of HIV prevention, care, and treatment services for MARPs.
WHO's first tranche of technical assistance, to be conducted in 2010, will provide critical direction to Ukraine's MAT service delivery program. This includes the identification of a range of MAT treatment models assessed for feasibility and cost effectiveness. WHO will also assist with the development of a set of standardized treatment models and related normative guidelines. In addition, WHO will support the drafting of a costed operational plan for scale up to reach National AIDS Program targets of MAT provision for 20,000 injection drug users (IDUs).
WHO supports the USG strategy for health systems strengthening in service delivery quality and improving cost effectiveness and financing of MAT services. This is in line with Ukraine's National AIDS Program strategic goals and objectives, which include the provision of MAT services to MARPs. WHO also contributes to the cross-cutting issue of gender and in particular, in increasing gender equity in HIV/AIDS activities. Among other issues, WHO will assess the effectiveness of reaching female IDUs with integrated MAT since they have considerably lower rates of accessing MAT services than their male counterparts.
